Exelixis (EXEL) Wells Fargo 21st Annual Healthcare Conference summary

Financial strength supports concurrent investment in all strategic areas. Capital allocation is balanced across R&D, business development (primarily GI and GU), and share buybacks, with $2.9 billion in buybacks completed and $600 million remaining. Early-stage pipeline and business development are prioritized to enable new programs and scale the company. Focus on maximizing CABO's value while investing in zanza, with a transition period expected through 2026 and a handoff as CABO faces loss of exclusivity in 2031. CABO's growth target remains at $3 billion, driven by RCC and NET indications through 2029. Slower-than-expected ramp in NET due to longer intervals between scans and therapies, but overall market potential remains unchanged. New patient market share for CABO in NET is around 45–47%, indicating strong penetration. NET is seen as a billion-dollar opportunity at current pricing, with prescription stacking expected to drive long-term revenue.